Keywords: phase, ii, results, agouron, thymitaq, pharmaceuticals, reported

Phase II Results With Agouron's Thymitaq

Article | 27 November 1995

Agouron Pharmaceuticals has reported the interim results of its Phase II trials of Thymitaq (AG337), its selective thymidylate synthase inhibitor, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in